Engineered virus therapy eradicates cancer in mice with single treatment.

Scientists claim a new therapy could eradicate cancer in a single treatment.

The breakthrough involves a virus engineered to hunt and destroy tumor cells directly.

Researchers at the University of Pennsylvania tested this approach on mice with aggressive tumors.

The modified virus, known as oncolytic immunotherapy, replicates only inside cancerous tissue.

It triggers the immune system to recognize and attack remaining cancer cells.

In trials, treated mice remained tumor-free for over a year without further intervention.

Control groups receiving standard care saw tumors grow rapidly within weeks.

The therapy showed no signs of harming healthy organs or causing systemic side effects.

Lead researcher Dr. Daniel Anderson notes the virus acts like a biological scalpel.

"We observed complete elimination of established tumors in multiple mouse models," he stated.

Current treatments often require lifelong medication to manage recurring disease.

This method aims to provide a permanent solution rather than temporary symptom control.

Clinical trials in humans are now planned to begin within the next two years.

Regulatory agencies will review safety data before approving the therapy for widespread use.

Critics caution that results in mice do not always predict human outcomes accurately.

They argue larger, longer studies are essential before claiming a one-shot cure.

The pharmaceutical industry watches closely as costs and production scales become major hurdles.

Manufacturing enough virus for millions of patients remains a significant engineering challenge.

If successful, this approach could revolutionize how oncology departments operate globally.

It represents a shift from managing chronic illness to achieving actual remission.

Investors are already funding follow-up studies to accelerate the path to market approval.

A significant development in radiotherapy treatment for prostate cancer has emerged from a recent clinical trial, suggesting that the procedure could be completed in a single high-dose session for the majority of patients. Earlier this month, certain radiotherapy facilities in England began transitioning patients from the standard regimen, which requires approximately twenty sessions, to a new high-power version delivered in five. Building on this progress, an early-stage trial conducted by the Oncology Institute of Southern Switzerland indicates that the treatment duration may be safely reduced further to just one session.

The technique involved in this advancement is known as stereotactic radiotherapy, or SABR in the UK and SBRT in the United States. This precision method utilizes higher radiation doses and directs beams at the tumor from multiple angles. By concentrating the radiation so effectively, medical professionals can shorten the number of required sessions while simultaneously minimizing the risk of tumor regrowth or metastasis and protecting surrounding healthy tissue. Charities have characterized this potential reduction in sessions as transformative, noting that it would expedite the clearing of waiting lists and alleviate the burden on patients who currently face numerous hospital visits.

Some NHS hospitals commenced the use of SABR for prostate cancer this month following prior UK-led trials that validated its efficacy over a five-session course. NHS England has confirmed that all 48 centers will possess the necessary machinery and staffing to offer SABR within three months. However, the organization stated it will await further data from ongoing trials before determining whether to fully adopt the "one and done" approach as standard practice.

The study focused on single-dose treatment administered to 43 men with localized prostate cancer across five hospitals in Europe and the United States. According to the analysis, 92.9 percent of these participants remained free of prostate cancer three years later, a metric determined by PSA blood test results. The research findings were published in the medical journal *JAMA Oncology*, where the authors noted that while single-fraction SBRT remains a promising strategy, its definitive role requires confirmation through larger cohorts with extended follow-up periods. They concluded that the current results merit serious consideration regarding the potential role of single-fraction radiotherapy.

Professor Peter Johnson, national clinical director for cancer at NHS England, emphasized that the health service is actively transforming treatment options for thousands of men. He highlighted that a five-dose high-powered precision radiotherapy is already being rolled out to target the disease more effectively. He added that NHS England will continue to monitor emerging research evidence with a commitment to ensuring patients receive the most effective treatments available.

David James, director of patient projects and influencing at Prostate Cancer Research, welcomed the findings, stating that any safe reduction in treatment burden is worthy of exploration. He described the prospect of treating some patients in a single session rather than over multiple visits as transformative for both individuals and the NHS. However, he cautioned that the current study was an early-phase trial involving a relatively small patient group, underscoring the need for larger studies with longer follow-up to validate the approach. He stressed that sustained investment in research is essential to accelerate the development of treatments that are not only effective but also less disruptive to daily life and more efficient for the healthcare system.

Simon Grieveson, assistant director of research at Prostate Cancer UK, pointed out that recent advancements have already allowed many men to undergo radiotherapy in five sessions instead of the previous twenty, significantly cutting hospital time and easing pressure on the NHS. He expressed excitement about the possibility of reducing the schedule to a single session, which would make treatment quicker and easier for patients. Nevertheless, he reiterated that while the results are promising, the current trial involved a small number of men. He called for larger trials that directly compare this shorter schedule with current practice to ensure that reducing treatment to one session works equally well without causing increased side effects. He also noted the importance of ensuring patients receive the appropriate treatment, as some men with lower-risk prostate cancer might be safely monitored without undergoing treatment altogether. If future trials confirm the safety and efficacy of the single-session method, it could represent another major leap forward in prostate cancer management.